London, UK (PRWEB) December 12, 2012
Monoclonal antibodies (mAb) represent one of the fastest growing segments of the global pharmaceutical market. In 2010, mAb market revenues amounted to more than USD 42.5 billion. Amgen Inc, Johnson & Johnson, Novartis AG, Eli Lilly and Company Biogen Idec, Merck & Co Inc, Abbott Laboratories and Roche Holding Ltd. are amid leading companies on the mAb market. The U.S. and Japan are the most prominent country markets for mAb.
New research report “Monoclonal Antibody Partnering Terms and Agreements” elaborated by CurrentPartnering has been recently published by Market Publishers Ltd.
Title: Monoclonal Antibody Partnering Terms and Agreements
Published: December, 2012
Price: US$ 2,695.00
The report delves into the monoclonal antibody market and reviews partnering deals and agreements in 2007-2012. The research study provides an extensive analysis of the mAb dealmaking directory by deal type, stage of development and by therapy indicators. Besides, the report thoroughly examines monoclonal antibody deals by technology type. The report offers comprehensive assessment of partnering deals and points out key market trends. It also indicates top companies active in the market and includes bigpharma monoclonal antibody partnering company profiles. Moreover, the research contains contract documents, deals’ records and their financial terms.
Reasons to Buy:
More new market research reports and databases by the publisher can be found at CurrentPartnering page.